Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain

Yuan Zhu, Mario I. Romero, Pritam Ghosh, Zhengyi Ye, Patrick Charnay, Elizabeth J. Rushing, Jamey D. Marth, and Luis F. Parada

1Center for Developmental Biology and Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9133, USA; 2Howard Hughes Medical Institute, University of California San Diego, La Jolla, California 92039, USA; 3Ecole Normale Superieure, Paris, France; 4Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9133, USA

Neurofibromatosis type 1 (NF1) is a prevalent genetic disorder that affects growth properties of neural-crest-derived cell populations. In addition, approximately one-half of NF1 patients exhibit learning disabilities. To characterize NF1 function both in vitro and in vivo, we circumvent the embryonic lethality of NF1 null mouse embryos by generating a conditional mutation in the NF1 gene using Cre/loxP technology.

Introduction of a Synapsin I promoter driven Cre transgenic mouse strain into the conditional NF1 background has ablated NF1 function in most differentiated neuronal populations. These mice have abnormal development of the cerebral cortex, which suggests that NF1 has an indispensable role in this aspect of CNS development. Furthermore, although they are tumor free, these mice display extensive astrogliosis in the absence of conspicuous neurodegeneration or microgliosis. These results indicate that NF1-deficient neurons are capable of inducing reactive astrogliosis via a non-cell autonomous mechanism.

[Key Words: Neurofibromatosis; tumor suppressor; animal models; knockouts; astrogliosis]

Received October 25, 2000; revised version accepted January 31, 2001.
Loss of heterozygosity (LOH) at the NF1 locus has been identified in pheochromocytomas (Xu et al. 1992), neurofibrosarcomas (Legius et al. 1993), and myeloid leukemias (Side et al. 1997). However, only a small percentage of benign neurofibromas, the hallmark feature of NF1, exhibit NF1 LOH (Colman et al. 1995; Sawada et al. 1996). This may in part be caused by the heterogeneous nature of neurofibromas, which are composed of Schwann cells, neurons, fibroblasts, and perineurial cells (Peltonen et al. 1988). Whether these heterogeneous tumors arise from NF1 LOH at one or all cell types remains to be determined.

NF1 homozygous [NF1−/−] mice die in utero because of abnormal cardiac development (Brannan et al. 1994; Jacks et al. 1994). NF1 heterozygous (NF1+/−) mice are viable and fail to develop features of human NF1, such as neurofibromas and cafe-au-lait spots, but do develop specific malignancies, including pheochromocytomas and myeloid leukemias in later life (Jacks et al. 1994). Thus, like many tumor suppressor knockout mice (Jacks 1996; Ghebranious and Donehower 1998; McClatchey and Jacks 1998), NF1+/− mice have failed to replicate the human condition with fidelity.

There are several nontumor syndromes that are associated with NF1 disease. For example, 35%–65% of NF1 children display specific learning disabilities (North 1999). Consistent with studies in human NF1, NF1+/− mice display spatial learning disability, which can be overcome by extended training (Silva et al. 1997). Guo et al. (2000) reported that Drosophila NF1 mutants have learning disabilities as well. The mechanisms underlying learning disability in both human and mouse NF1 brains remain unknown. However, these observations suggest that NF1 may play an important role in neuronal development and physiology.

To study the physiological role of NF1 in neural development and to generate a better model for human NF1, we have used the Cre/loxP system (Gu et al. 1994) to generate a conditional allele [NF1floxed] at the NF1 locus. In this study, we describe the effectiveness of the NF1 conditional allele for studying the function of neurofibromin in differentiated neurons. The data support the model that loss of NF1 function in neurons can have non-cell autonomous consequences in vivo. This NF1 mouse model provides a valuable tool to study neuronal and glial phenotypes associated with human NF1 disease.

**Results**

*Generation of NF1 conditional mutant mice by Cre/loxP*

Exon 31 is essential for NF1 gene function in both humans and mice (Brannan et al. 1994). Therefore, we designed a gene-targeting strategy that flanked exons 31 and 32 with loxP sites, such that both exons can be deleted by Cre-mediated recombination (Fig. 1A). The targeting vectors were transfected into embryonic stem (ES) cells and 2 of 415 clones contained the targeted alleles as determined by Southern blot analysis (Fig. 1B). The homologous recombinant clones were injected into C57BL/6 blastocysts and subsequently transmitted into the germ line. Homozygous NF1floxed mice and compound heterozygous NF1floxed−/− mice were generated through appropriate crosses, and both strains are viable and fertile (Fig. 1C,D). To further characterize the NF1floxed allele, we monitored a cohort of 35 NF1floxed/floxed and 29 NF1floxed−/− mice over a period of 14 mo. Unlike NF1floxed/floxed mice that exhibited a typical wild-type survival profile, NF1floxed−/− mice began to die at 10 mo of age, and only 80% survived beyond 14 mo (Fig. 1E). Thus, the NF1floxed−/− survival profile is indistinguishable from that of NF1+/− mice (Jacks et al. 1994). Based on this survival result, the NF1floxed allele behaves like a wild-type allele despite the presence of two loxP sites and a neo cassette in the introns flanking exons 31 and 32.

To determine whether Cre-mediated recombination in the NF1floxed allele results in a null allele, we crossed NF1floxed/floxed mice with a transgenic strain that expresses Cre recombinase in the mouse germ line (Voiculescu et al. 2000). The resultant progeny harbor a recombined allele [NF1Δ] and a wild-type allele, NF1+/−. These mice were bred into the NF1 null background to generate compound heterozygous NF1Δ−/− progeny. NF1Δ−/+ embryos are indistinguishable from NF1+/− embryos, which are characterized by an enlarged heart, peripheral edema, hemorrhage, small unpigmented eyes, and which die at E13.5 because of cardiac abnormalities [Fig. 1F; Brannan et al. 1994; Jacks et al. 1994]. These results indicate that the NF1floxed allele is susceptible to Cre-mediated recombination in vivo and that the recombined NF1floxed allele [NF1Δ] is a phenocopy of the null allele. We conclude that the NF1floxed allele represents a functional conditional allele.

*NF1 mutant dorsal root ganglion neurons gain neurotrophin independence because of direct loss of NF1 function*

We showed previously that, unlike wild-type counterparts, cultured embryonic NF1+/− sensory and sympathetic neurons survive without added neurotrophins (Vogel et al. 1995). These data supported the model that loss of NF1 function results in constitutive activation of the ras pathway downstream from Trk receptors, even in the absence of neurotrophins. However, those studies could not exclude the possibility that loss of NF1 function developmentally altered neuronal precursors, enabling them to undergo differentiation without requiring neurotrophin signaling. To examine whether the neurotrophin independence that is acquired by NF1+/− neurons is direct, we repeated the neurotrophin survival experiments using dorsal root ganglion (DRG) neurons cultured from NF1floxed/floxed or NF1floxed−/− embryos. NF1floxed−/− cultured embryonic DRG neurons were infected with a cytomegalovirus (CMV) promoter-driven, Cre-expressing recombinant adenovirus at varying multiplicities of infection (MOI). Cre-mediated recombination was monitored by Southern blot analysis (Fig. 2A,B).
MOI >20 was sufficient to mediate recombination of all the NF1flox alleles in cultured DRG neurons (Fig. 2B). Cre-adenovirus infected cultures (MOI = 50) of E13.5 NF1flox/flox or NF1flox/− DRG neurons were monitored for survival in the absence of neurotrophins. After 3 d of infection, NGF was removed by medium dilution.
and addition of neutralizing anti-NGF antibody. Only the cultures that were infected with Cre-adenovirus [resulting in NF1 deficiency] persisted in the absence of NGF [Fig. 2C]. Uninfected cultures or cultures that were infected with a CMV LacZ-expressing adenovirus underwent classical, neurotrophin-deprivation cell death [Vogel et al. 1995]. These data provide direct evidence that neurotrophin independence resulted from functional loss of NF1 in the differentiated neuronal cultures and further validate the functionality of the conditional NF1flox allele in primary cultures.

**Synapsin I–Cre transgenic mice specifically express Cre recombinase in differentiated neurons**

To assess the role of NF1 in neurons, we produced and characterized a neuronal-specific Cre recombinase transgenic (Tg) strain. In this strain, Cre expression is controlled by the rat Synapsin I promoter, which has been shown to drive transgene expression specifically in neuronal cells [Hoesche et al. 1993]. To examine the temporal and spatial pattern of Cre activity, we crossed SynI–Cre Tg mice to a LacZ indicator Tg strain (H9252-actin/LacZ) that requires Cre recombinase activity to permit expression of the β-galactosidase (β-gal) gene [Tsien et al. 1996]. We can detect Cre function as early as E12.5, when β-gal activity is restricted to brain, spinal cord, and DRG [Fig. 3A–D]. Histological analysis showed that Cre activity is mainly distributed in differentiated neurons, outside the ventricular regions of the brain and spinal cord [data not shown]. These data are consistent with endogenous Synapsin I gene expression [Melloni and DeGennaro 1994].

To assess whether Cre activity remains restricted to neurons in adult mice, we first performed PCR assays on genomic DNA isolated from brain, spinal cord, heart, lung, kidney, and liver of NF1flox;SynI–Cre mice. Cre-mediated recombination was only detected in brain and spinal cord [data not shown]. We next performed double immunohistochemistry using anti-LacZ (detecting Cre activity) and anti-NeuN (neuronal marker; Mullen et al. 1992) antibodies on brain and spinal cord sections from double transgenic SynI–Cre;LacZ mice. Figure 3E–P show representative examples of double labeling from the cortex, spinal cord, and hippocampus. NeuN immunoreactivity (red signal) essentially colocalized with LacZ reactivity (green signal), which indicated that Cre activity is mainly distributed in neurons. Unlike most areas of the brain, LacZ immunoreactivity is low in the cerebellum, where only few Purkinje cells remain positive [Fig. 3Q–S].

To directly examine the status of the floxed NF1 allele when exposed to Synapsin I-Cre expression, NF1flox/+;SynI–Cre mice were bred to NF1flox/flox mice, resulting in 25% of the offspring with NF1flox/flox;SynI–Cre genotype. We refer to the neuronal-specific NF1 mutant mice as, NF1SynIKO. To verify neuron-specific Cre activity, we performed immunohistochemistry using anti-NF1 antibody on brains and spinal cords from control and NF1SynIKO mutant mice. Although cortical and spinal cord neurons from control mice contain strong neu-
Characterization of Synapsin I-Cre transgene (Tg) expression. E12.5 embryos (A) Cre Tg, (B) LacZ Tg, (C) and (D) Cre/LacZ double Tg were subjected to LacZ staining. Only the compound transgenic mice exhibit Cre-mediated activation of the β-galactosidase gene. Double-labeling immunooanalysis of Cre/LacZ double Tg with anti-NeuN and anti-LacZ antibodies for the cortex (E–J), spinal cord (K–M); hippocampus (N–P); and cerebellum (Q–S). Colocalization of LacZ and NeuN signals indicate that Cre-mediated recombination specifically occurs in differentiated neurons. Of note, the neuronal marker, NeuN is not expressed in the Purkinje cells. Ctx, cortex; SC, spinal cord; Hp, hippocampus; andCb, cerebellum. Objective magnification: E–G and N–P, 20×; H–M and Q–S, 40×.
rolifibron staining (Fig. 4A,B,D; Norland et al. 1993),
neurofibromin immunoreactivity was completely lost in 
fN1SynIKO counterparts (Fig. 4E,F,H). However, consistent 
with the LacZ staining data, many mutant Purkinje 
cells remain positive for neurofibron [Fig. 4G]. Taken 
together, the data indicate that neuron-specific expres-
sion of Cre recombinase results in ablation of neurofi-
bromin in most fN1SynIKO neurons.

Cre recombinase is not expressed in astroglia
Most astrocytes do not normally express detectable NF1 
(Daston et al. 1992). Therefore, to ensure that Cre-medi-
ated recombination does not occur in fN1SynIKO astro-
cyes, we used two approaches. First, we crossed 
fN1SynIKO mice into two LacZ indicator strains (β-ac-
tin–LacZ and Rosa26–LacZ), which gave similar results. 
Rosa26–LacZ has been widely used and documented to 
express LacZ in all cells (Soriano 1999). Double labeling 
with antibodies directed against LacZ and astrocyte-spe-
cific glial fibrillary acidic protein (GFAP) was performed 
on SynI–Cre;Rosa26–LacZ brain sections. We focus on 
the hippocampus because it contains the highest levels 
of endogenous GFAP-positive astrocytes, although similar 
results were observed in all regions of the CNS. As 
shown in Figure 5A,C, LacZ immunoreactivity is mainly 
localized in the neuronal layer of CA2/3 (Fig. 5A) and 
dentate gyrus (Fig. 5C) and does not colocalize with 
GFAP. A positive control using a transgenic strain that 
expresses Cre recombinase using a transgenic strain that 
expresses Cre recombinase both in neurons and glia, and 
therefore exhibits colocalization of LacZ and GFAP, is 
indicated in Figure 5A, inset. To rule out the possibility 
that Cre-mediated deletion may occur more efficiently 
in the floxed NF1 locus than in the floxed LacZ locus 
(which could result in astrocytes that are NF1 deficient 
but LacZ negative), we performed double labeling with 
anti-Cre and anti-GFAP [Fig. 5B,D]. Like LacZ, Cre ex-
pression was confined to neuronal layers and did not 
coincide with GFAP-positive astrocytes. Thus, we con-
clude that most, if not all fN1SynIKO astrocytes do not 
undergo Cre-mediated recombination and that SynI–Cre 
Tg mice primarily and specifically express the Cre re-
combinase transgene in most populations of differenti-
ated neurons. Consequently, the phenotypes described 
below are the result of NF1 loss in neurons.

Loss of NF1 in neurons affects cortical development
There was no apparent embryonic lethality occurring in 
fN1SynIKO mice, and newborn fN1SynIKO pups were indi-
stinguishable from their control littermates (NF1flox/
fl or flox/fl+;SynI–Cre, data not shown). These results 
indicate that neuronal NF1 function is not required for 
survival through birth. Three to four days after birth, 
fN1SynIKO mice began to exhibit growth retardation 
that was sustained into adulthood, with a reduction in 
both weight and size that stabilized at −50% of normal 
littermates [Table 1; data not shown]. Otherwise, the 
fN1SynIKO mice appeared to be normal and were fertile.
We monitored size and weight of internal organs in adult 
fN1SynIKO mice and found that the kidney, heart, liver, 
and spleen showed a proportional reduction in both 
weight and size [Table 1; data not shown]. In contrast, we 
saw limited reduction in brain size [Table 1]. Separate 
analysis of different structures of the brain revealed that 
reduced brain weight is limited to the forebrain [Table 1]. 
Histological analysis of fN1SynIKO brains re-
vealed a conspicuous defect in the cerebral cortex, 
which is characterized by a reduction in cortical 
thickness and an apparent increase in cell density 
(Fig. 6A–H). Morphometric analysis of serial coronal sec-
tions throughout the anterior-to-posterior length of 
fN1SynIKO and control brains indicated a significant re-
duction in mutant cortical thickness by ~20% [Fig. 6A–

---

Figure 4. fN1SynIKO mice lose neurofibron immunoreactivity in most neuronal populations. (A–D) Anti-NF1 immunoreactivity 
in the cortex (Ctx), cerebellum (Cbx), and spinal cord (SC) of control mice showing dark staining of neurons. (E–H) Loss of NF1 staining 
in the majority of neuronal populations in the mutant mice. An exception, however, is a subset of the Purkinje neurons in the Cbx 
(G), which retain NF1 immunoreactivity. A–C are from the same section, as are E–G. Scale bar, 50 µm.
This deficit appears to be specific to the cerebral cortex, given that the dorso–ventral and the medio–lateral axes (excluding the cortex), as well as the hippocampus and hindbrain, were not affected in NF1SynIKO brains (Fig. 7C).

Table 1. Size and weight analysis of NF1SynIKO mice

| Genotype | Body     | Forebrain | Hindbrain | Kidney   |
|----------|----------|-----------|-----------|----------|
| Control  | 23.13 ± 2.16 | 0.39 ± 0.02 | 0.14 ± 0.01 | 0.22 ± 0.01 |
| Mutant   | 11.81 ± 1.98* | 0.33 ± 0.02* | 0.13 ± 0.01 | 0.13 ± 0.02* |
| Percent  | 51.1% | 84.6% | 92.9% | 59.0% |

The reduction in NF1SynIKO body (48.9%) and kidney (41.0%) weight were statistically significant ($P < 0.01$). A separate evaluation of forebrain and hindbrain weight revealed a significant 15% reduction ($P < 0.01$) in forebrain, whereas the hindbrain was not significantly different from that of control littersmates. Percent indicating weight percentage in mutants to controls.

* $P < 0.01$.
mension of the neuronal NF1 mutant cerebral cortex is not likely to be the result of reduced cell number [Fig. 6A–H]. The increase in cell density often resulted in less apparent lamination, although we detected intact layered structure in some regions of the NF1^{SynIKO} mutant brains [Fig. 6B,F].

To evaluate neuronal differentiation in NF1^{SynIKO} brains, we performed immunohistochemistry using anti-MAP2 [dendritic marker] antibody. As shown in Figure 6I,J, the pattern of MAP2 immunoreactivity was indistinguishable between control and mutant brains, except that the mutant cortex tended to show greater MAP2 immunoreactivity consistent with higher neuronal density. We also examined cortical, hippocampal, and Purkinje neurons in NF1^{SynIKO} mutant brains using antibodies against several calcium-binding proteins, includ-
ing calbindin, parvalbumin, and calretinin. We observed no apparent abnormalities (data not shown).

To test whether high neuronal density in the mutant cortex results in abnormal organization of dendrites and axons, we performed Golgi staining on control and mutant brains to permit visualization of individual neurons and their dendritic arbors within the cortex [Ramon y Cajal 1904]. Golgi staining indicated that NF1SynIKO mutant neurons have normal arborization of dendrites and axons when compared to control counterparts (Fig. 6K, L). Collectively, these data show that NF1SynIKO mutant mice have normal neuronal development but display high cell density in a reduced cerebral cortex, which often results in less apparent lamination. The mechanistic basis underlying the cortical defect remains to be elucidated.

NF1 SynIKO mutant brains display astrogliosis

Because neuronal development in NF1SynIKO brains is relatively normal, we examined additional cell populations. Brains from adult control and mutant mice were serially sectioned and subjected to immunohistochemistry using the astrocyte-specific anti-GFAP antibody. Ten of ten NF1SynIKO mice displayed extensive GFAP immunoreactivity, which reflects astrogliosis throughout the cerebral cortex, hippocampus, and brainstem [Fig. 8]. Figure 8A–D shows four levels of coronal brain sections from rostral to caudal. The mutant brains [right panels] showed significantly higher GFAP levels compared with control counterparts [left panels]. Intense GFAP staining was especially prominent in the cerebral cortex, where endogenous GFAP immunoreactivity is normally low [Fig. 8A–D]. High magnification showed the GFAP-positive cell morphology to be typical of reactive astrocytes [Fig. 8E–L; Ridet et al. 1997].

To confirm the reactive nature of NF1SynIKO astrocytes, we performed immunohistochemistry with a second independent anti-GFAP antibody on thin sections (see Materials and Methods). As shown in Figure 8M–O and Figure 8R–T, the mutant hippocampus showed increased numbers of GFAP-positive astrocytes that are hypertrophic with thicker and increased processes. Other brain regions also showed dramatic increase in the number of GFAP-positive astrocytes, including the brainstem [Fig. 8U, V], where there is little endogenous GFAP immunoreactivity [Fig. 8P, Q]. To quantify the degree of GFAP-positive astrocyte increase, we counted GFAP-positive cells in the cerebral cortex, hippocampus, and brainstem. As indicated in Figure 9, there is 4.4-fold increase in the number of GFAP-positive astrocytes in the cerebral cortex, 1.6-fold increase in the hippocampus, and ninefold increase in the brainstem of NF1SynIKO mice as compared to the control counterparts.

NF1 SynIKO brains do not develop neuronal degeneration or microgliosis

The data presented above support the notion that neuron specific loss of NF1 function leads to astrogliosis through an indirect mechanism. Because astrogliosis is often associated with neuronal degeneration [Ridet et al. 1997], it is possible that neuronal loss of NF1 causes neuronal degeneration, which leads to induction of astrogliosis. We examined NF1SynIKO brains for evidence of necrosis or apoptosis using Nissl staining and TUNEL assays and were unable to detect evidence of degenerat-
Figure 8. NFI<sup>S648</sup>KO mice display extensive astrogliosis. Serial coronal sections were cut at 50 µm thickness (cryostat) or 5 µm thickness (paraffin), and subjected to GFAP immunohistoanalysis. (A–D) Four sections from rostral to caudal, with the left hemispheres in each panel from control mice and the right hemispheres from mutant mice. Note the overall darker brown staining in the right hemispheres, indicating extensive astrogliosis in the mutant brains. (E–H) High magnification of the control cortex [the boxed area of the left hemisphere in A–D]. (I–L) High magnification of the mutant cortex [the boxed area of the right hemisphere in A–D]. (M–O) Control and (R–T) mutant hippocampus. Note the hypertrophic nature of the reactive astrocytes [compare T to O]. Control [P,Q] and mutant [U,V] brainstem. Scale bar: A–D, 1 mm; E–V, 50 µm.
ing neurons (data not shown). A second normal response to CNS injury or cell death is the induction of microglia into the region. Microgliosis is characterized by cellular hypertrophy and increased proliferation (Streit et al. 1999). To examine whether NF1SynIKO brains develop microgliosis, we used an antibody against macrophage surface antigen (anti-mac1; Rabchevsky et al. 1998) to detect the morphology of microglia. Serial sections from all regions of NF1SynIKO brains were compared to normal counterparts, and no evidence of microgliosis was found (data not shown). Taken together, these results indicate that loss of NF1 in neurons does not elicit the classical morphological features of neuronal degeneration and microgliosis, but, rather, may alter normal neuronal physiology, thus exerting an effect on surrounding astrocytes (Kraig et al. 1991; Steward et al. 1991).

Loss of NF1 in neurons results in activation of endogenous MAP kinase

To investigate further the mechanism underlying astrogliosis in NF1SynIKO brains, we examined the activity of MAP kinase, a downstream component of ras/NF1 signaling that is activated in some human reactive astrocytes (Mandell and VandenBerg 1999). First, proteins were extracted from different regions of NF1SynIKO and control brains, including the cortex, hippocampus, brainstem, and cerebellum, and subjected to Western blot analysis with anti-phosphorylated erk (P-erk) antibody, which recognizes the active form of MAP kinase. All regions of NF1SynIKO brains showed significantly increased P-erk levels as compared with controls (Fig. 10A,B). We next localized activation of MAP-kinase using immunohistochemistry. Immunoanalysis revealed that NF1SynIKO mutant brains (Fig. 10D,F,H) contain significantly more P-erk positive cells than do control brains (Fig. 10C,E,G). In particular, Layers II/III and VI of the mutant cerebral cortex showed conspicuous astrogliosis (Fig. 8A–D) and always had a significant increase in number of P-erk positive cells (Fig. 10E–H). In all regions examined, the large majority of P-erk positive cells has unambiguous neuronal morphology (Fig. 10E,F,H) and coexpress a neuronal marker, NeuN (data not shown). Taken together, these results indicate that loss of NF1 in neurons resulted in activation of MAP kinase in these cells, with no evidence for similar activation in reactive astrocytes.

Finally, to examine whether the observed increase in the number of GFAP-positive astrocytes results from excess proliferation of glial precursors or mature astrocytes, we employed in vivo BrdU incorporation assays. We examined three neonatal and three adult (5-month-old) NF1SynIKO and control brains and failed to detect an increase in proliferation (data not shown). The results suggest that increased proliferation may not play a major role in this astrogliosis model (see Discussion).

NF1SynIKO mice are tumor free

Although extensive astrogliosis was found in NF1SynIKO brains, we failed to detect the formation of optic gliomas and astrocytomas. In total, 29 NF1SynIKO mice were monitored over a period of 14 mo, followed by complete necropsy and histological analysis of the CNS. No evidence of tumor appearance was uncovered (data not shown). In the periphery, we dissected entire spinal cords together with intact DRG from five 14-month-old NF1SynIKO mice that were subjected to complete histological analysis and found no sign of neurofibroma formation (data not shown). Thus, loss of NF1 in differentiated neurons, although able to induce astrogliosis, is not sufficient to induce the formation of gliomas or neurofibromas. However, it remains undetermined whether neuronal loss of NF1 can contribute to tumorigenesis in combination with other genetic and/or epigenetic factors.

Discussion

The generation of knockout mice has provided insight into the role of NF1 in developmental processes, such as cardiac development and neuronal survival (Brannan et al. 1994; Vogel et al. 1995). However, the early lethality of NF1−/− mice limited these studies from extending into later developmental stages or adulthood. The generation of NF1 conditional mutants now permits more detailed examination of the physiological function of NF1 both in vitro and in vivo.
Previously, NF1 function has been studied in neurons, Schwann cells, and fibroblasts through isolation of primary cells from NF1−/− embryos (Kim et al. 1995; Rosenbaum et al. 1995; Vogel et al. 1995). The interpretation of these studies was hampered by the inability to distinguish a direct functional defect in mature cells from an indirect effect resulting from developmental abnormalities in precursor cells. With the conditional mutant, neurons or Schwann cells can be permitted to develop and differentiate in the wild-type state, and abla-

**Figure 10.** Activation of MAP kinase in NF1SynIK neurons. (A) (Top panel) Western blot analysis of tissues from different parts of control and mutant brains using anti-phosphorylated erk [P-erk] antibody. (Bottom panel) The same blot was stripped and reprobed with anti-P-erk antibody as a loading control. (B) P-erk and erk signals were quantified by densitometry [see Materials and Methods]. The level of P-erk in each sample is normalized to level of erk protein signal. Each number represents mean value ± standard error of the mean (SEM) of ratio of P-erk levels of three mutants to three controls. Sections of cerebral cortex from control (C) and mutant mice (D) were analyzed with anti-P-erk antibody. The mutant cortex exhibits greater number of phospho-erk positive cells corresponding to neurons and not to reactive astrocytes. E and G are high magnification of the top and bottom boxed area of C; F and H are high magnification of the top and bottom boxed area of D. Ctx, cerebral cortex; Hp, hippocampus; Bs, brainstem; Cb, cerebellum; CC, corpus callosum. Scale bar, 100 µm.

*In vitro*

Previously, NF1 function has been studied in neurons, Schwann cells, and fibroblasts through isolation of primary cells from NF1−/− embryos (Kim et al. 1995; Rosenbaum et al. 1995; Vogel et al. 1995). The interpretation of these studies was hampered by the inability to distinguish a direct functional defect in mature cells from an indirect effect resulting from developmental abnormalities in precursor cells. With the conditional mutant, neurons or Schwann cells can be permitted to develop and differentiate in the wild-type state, and abla-
NF1 conditional knockouts exhibit astrogliosis

NF1 in the CNS

To date, we have observed two CNS phenotypes in NF1\textsuperscript{SynIKO} mice (cortical compression and astrogliosis). In contrast to other brain regions, NF1\textsuperscript{SynIKO} cerebral cortices are statistically smaller by 20% than the controls. One study suggested that brains of 10 NF1 patients have abnormal cortical lamination (Rosman and Pearce 1967). Whether less apparent lamination in both mouse and human results from increased neuronal density remains to be determined. Nonetheless, the compression that is found uniquely in the cerebral cortex indicates a unique role for NF1 in cortical development. This feature may be of relevance to a diverse set of disorders termed “micrencephally,” that result in reduced size of forebrain and cerebellum (Hatten 1999). In this context, recent reports of an FGF-2 mouse knockout indicated cAMP-mediated signaling pathways (Guo et al. 1997; The et al. 1997). For the reasons cited above, the NF1 conditional system should provide effective means of addressing the role of NF1 in cAMP-mediated signaling pathways in primary cells, such as neurons and Schwann cells.

The role of NF1 in astrogliosis

In response to infection, injury, or neurodegeneration, CNS astrocytes undergo hypertrophy, possible proliferation, and altered gene expression, including up-regulation of astrocytic GFAP (Ridet et al. 1997). One postmortem case study reported three NF1 patients with extensive astrogliosis. However, the fact that two of the patients had undergone chemotherapy has confounded the interpretation of the underlying cause (Nordlund et al. 1995). Two recent reports have suggested that some NF1 heterozygous mutant mice may have increased GFAP-positive astrocytes (Gutmann et al. 1999; Rizvi et al. 1999). In one instance, mild increases [40%] were reported throughout the brain (Gutmann et al. 1999), whereas a second study reported significant increases only in the periaqueductal gray and nucleus accumbens with little evidence in other structures (Rizvi et al. 1999). We were unable to detect evidence of significantly increased GFAP-positive cells in heterozygous NF1+/− mice (see Materials and Methods). Our results provide the first direct evidence that loss of both NF1 alleles in neurons is sufficient and required to induce astrogliosis in the CNS. These data do not support the idea that haploinsufficiency could lead to this phenotype.

Critical to our conclusions is the specificity of the synapsin promoter–Cre transgenic mouse that is employed in this study. We therefore employed detailed and exhaustive immunohistochemical assays to assess the expression of lacZ reporters, of endogenous NF1, and of Cre recombinase in the context of two independently derived LacZ indicator mouse strains [β-actin/LacZ and Rosa26–LacZ], as well as in NF1\textsuperscript{SynIKO} mice.

Finally, activation of MAP kinase was only observed in neurons, not astrocytes, thus further supporting that \textit{ras} activation only occurred in neurons of NF1\textsuperscript{SynIKO} mice. In an ongoing study, we have ablated NF1 in neural precursor stem cells, which results in NF1 loss in both mature neurons and glia (Y. Zhu, P. Ghosh, A. Messing, and L.F. Parada, in prep.). The morphological phenotypes in the CNS of these mice are distinct from that of this study, and importantly, the astrocytes display conspicuous MAPK activation, which is never observed in NF1\textsuperscript{SynIKO} astrocytes. We therefore conclude that loss of NF1 is neuron specific and results in non-cell autonomous consequences.

A unique model for astrogliosis and learning disability

To date, NF1\textsuperscript{SynIKO} mice give no evidence of neurofibromas or optic gliomas that are common features of human NF1 (Riccardi 1999). This suggests that loss of NF1 in differentiated neurons is not sufficient to induce tumor development despite the ability to induce astrogliosis in the CNS. \textit{Ras}-mediated signaling has been implicated in human gliomagenesis, given that activated mutations or amplification of the epidermal growth factor receptor (EGFR) gene have been found in a subset of human gliomas (Schlegel et al. 1994; Hayashi et al. 1997). However, astrogliosis in NF1\textsuperscript{SynIKO} mice is likely to be mediated through pathways other than \textit{ras}, given that MAPK activation was only present in neurons and not in reactive astrocytes. The simplest model for the observed astrogliosis is that a paracrine effect, mediated by NF1-deficient neurons, induces astrogial hypertrophy and GFAP induction (Rabchevsky et al. 1998). Alternatively, loss of NF1 may induce synaptic hyperactivity, which leads to astrocyte reactivity (Kraig et al. 1991; Steward et al. 1991). One interesting feature in this astrogliosis model is the absence of neuronal degeneration and microgliosis. The fact that most known cytokines,
such as CNTF and interleukin-6 (IL-6), can induce both astroglisis and microgliosis suggesting the existence of a unique signal from NF1-deficient neurons that only activates astrocytes, but not microglia [Ridet et al. 1997]. Among the known transgenic models, TGFα is the only identified cytokine that, when overexpressed in brain, leads to astroglisis but not to microgliosis [Rabchevsky et al. 1998]. The fact that TGFα binding to EGFR presumably activates the downstream MAPK pathway in reactive astrocytes suggests that TGFα is not likely to be the inducer for astroglisis in this context. Furthermore, the observation that there is no increase in proliferation during postnatal development and in adults suggests that astroglisis in this model is likely to be a consequence of hypertrophy and up-regulation of GFAP in preexisting differentiated astrocytes. This notion is consistent with the following two observations: There is no increase in the total number of cells and neurons in the mutant cortex, and the areas that contain lower numbers of endogenous GFAP-positive astrocytes, such as the cortex and brainstem, show more dramatic astroglisis than those areas that have higher numbers of GFAP-positive astrocytes, such as the hippocampus. However, it remains possible that increased proliferation occurs in mutant brains some time between P0 and 5 mo of age. These observations suggest that neuronal loss of NF1 leads to the activation of MAP kinase, exerting a signal to activate surrounding astrocytes, including up-regulation of GFAP. Future identification of this unique inducer will shed new insight into the underlying mechanism of astroglissippiogenesis and neuronal/glial interactions.

The fact that 30%–65% of NF1 children have learning disabilities [North 1999] and that NF1 is highly expressed in both embryonic and adult neurons [Daston and Ratner 1992, Daston et al. 1992, Huynh et al. 1994] suggests that NF1 may have an important role in CNS development. Preliminary results indicate that NF1SynIKO mice also display severe learning disability [Y. Zhu, R. Costa, L.F. Parada, and A.J. Silva, unpubl.]. It will be of interest to determine whether learning disability is the consequence of activated rás/MAPK pathway in neurons or of astroglisis interfering with synaptic function. Thus, NF1SynIKO mice may provide a unique model for one aspect of human NF1—learning disability.

Finally, through the use of two novel mouse strains [NF1floxed and Syn–Cre Tg], this study underscores the importance of revisiting retrospective studies of astroglisis in individuals with NF1. Correlation of this phenotype to those patients with learning disabilities may provide a key to dissecting the physiological basis for this important problem.

Materials and methods

Generation of NF1 flox mice

Two oligos were designed to generate a Sacl–Xbal linker containing a 34-bp loxP site and an EcoRI site (5′ primer, 5′ to 3′: CGGAATTCGATAACTTGCTATAGCATACATTATACGAAGTTAT; 3′ primer, 5′ to 3′: CTAGATAACTCGTATAATGTATGCTATACGAAGTTAT CGGAATTCGACT). The Sacl–Xbal linker was subcloned into the plax34 plasmid containing a PGKneo cassette [Jackson lab]. The EcoRI fragment containing the PGKneo and a loxP site retrieved from the above construct was subcloned into the EcoRI site of an 8.6-kb HindIII–PstI NF1 genomic DNA [Fig. 1A]. The resultant construct is designated pYZ05. The same Sacl–Xbal linker was subcloned into 5′ of 1.0-kb PstI–HindIII NF1 genomic DNA and designated pYZ04. The insert of the pYZ04 construct was modified at both ends with NotI linkers and subcloned into the NotI site of pYZ05. The resultant construct is designated pYZ07. The 11.6-kb HindIII fragment from the pYZ07 construct was subcloned into a modified pBS-KSII vector containing a thymidine kinase cassette. The final construct is designated pYZ08D [Fig. 1A]. ClI linearized targeting vector was transfected into R1 ES cells [Zhu et al. 1998].

Molecular analysis

NF1flox mice were genotyped by either Southern analysis [Fig. 1C,D] or a three-oligonucleotide primer PCR assay. Two primers (P1 and P3) from intron 30 of the NF1 gene were designed to detect a 480-bp band from the WT allele; a third primer (P4) from the neo gene and P1 were used to amplify a 350-bp band from the flox allele [Fig. 2A]. PCR was performed under the following conditions: 0.25 mM of dNTPs, 3.0 mM of MgCl₂, 0.2 µM of primers, and 2 units of Taq polymerase (GIBCO); and the program: 1 cycle of 94°C for 1 min; 30 cycles of 94°C for 30 sec; and 72°C for 1 min; followed by 72°C for 4 min. A sensitive PCR assay for detecting Cre-mediated recombination and completion of deletion was established as the following: Two primers (P1 and P2; Fig. 2A) were used to detect a 280-bp band that resulted from Cre-mediated recombination in the NF1flox allele. The P1 and P4 primers were used to detect the completion of Cre-mediated recombination. The PCR conditions are identical to that for NF1flox genotyping. Genotyping the Cre transgene was carried out by a PCR assay under the following conditions: 1.25 mM of dNTPs, 1.5 mM of MgCl₂, 0.4 µM of primers, and 2 units of Taq polymerase (GIBCO); and the program: 1 cycle of 94°C for 1 min, 55°C for 30 sec, 65°C for 30 sec, and 72°C for 1 min; and followed by 72°C for 2 min. The sequences for primers (5′ to 3′) are: P1, CTTCACAGTGATTGTGTGACCTGA; P2, CATCTCTAGTACGAAATG; P3, ACCCTTCTAGCTACGAAATG; P4, TGATT CCCATTTTGTTGCTTACAG; Cre1, CATGTTATTAGCCTGGCCCAAATGTTGCTG; Cre2, CATGTTATTAGCCTGGCCCAAATGTTGCTG; and CreNukATG, CGACCATGCCCAAGAAGGAGGAGTGC.

Primary culture

E13.5 NF1flox/flox or flox/– embryos were dissected, and DRG neurons were isolated and cultured in the presence of NGF (10 ng/mL, GIBCO) as described [Vogel et al. 1995]. Four hours after plating, the DRG cultures were either infected with LacZ- and Cre-adenovirus at MOI = 50 or mock infected. Three days later, NGF was removed from the culture by serial dilution and addition of anti-NGF neutralizing antibody (150 µg/mL, Boehringer Mannheim). Neuronal counts were performed every 24 hr for 5 d after plating.

Production and characterization of SynI–Cre Tg mice

The SynI–Cre transgene was constructed using the Sacl–Xhol 4.4-kb fragment of pBL4.3Syn–CAT, kindly provided by Dr. Manfred Kilian [Hoesche et al. 1993], containing the rat Syn-
Size and weight analysis of NF1<sup>SynIKO</sup> mice

NF1<sup>SynIKO</sup> control littermates were used to determine overall body size (horizontal and vertical dimensions in cm) and weight (g), as well as size of several internal organs including kidney, liver, and spleen. The brain was separated into forebrain and hindbrain for analysis.

Golgi-Cox staining

Animals were perfused with 0.9% buffered saline and their brains immersed in 40 mL of Golgi-Cox solution (Glaser and VanderLoos 1981) for 14 d. The brains were then vibratome-sectioned at 100 µm in PBS, mounted, and stained following a modified protocol (Kolb and McClimans 1986).

Immunohistochemistry

Free-floating sections were either cut at 50 µm on a freezing microtome or cut at 75 µm on a vibrotome. Paraffin sections were cut at 5 µm, deparaffinized and rehydrated. The color visualization of the primary antibodies was performed with a horseradish peroxidase system (Vectastain ABC kit, Vector). Slides were counterstained with hematoxylin, washed in H<sub>2</sub>O<sub>2</sub>, dehydrated with 100% EtOH three times for 1 min each, with xylene three times for 1 min each, and then mounted with permount. For immunofluorescence, slides were incubated with either Cy3-conjugated anti-rabbit/mouse or Cy2-conjugated anti-rabbit secondary antibodies at 1:200 dilution for 45 min at room temperature. Slides were then washed with PBS four times each and mounted with immu-mount (Shandon). The dilutions of primary antibodies used in this study were: LacZ (1:100, 5' and 3'); NeuN (1:500, Chemicon), MAP2 (1:100, Sigma), calbindin (1:1000, SWant), parvalbumin (1:2000, SWant), GFAP (anti-mouse, 1:100, Pharmingen), GFAP (anti-rabbit, 1:5000, DAKO), mac1 (anti-mouse, 1:250, Chemicon), Cre (1:200, Novadon), NF1 (a gift from Nancy Ratner, 1:2000), David Gutmann, 1:100), P-erk (Biolabs, 1:200), and S100 (Signet, 1:1000).

Morphometric analysis of cerebral cortex

Cryostat sections were serially cut at 50-µm thickness and subjected to H&E staining and NeuN immunohistochemistry. Five coronal brain sections per animal (n = 5 per genotype) were evaluated at 500-µm intervals from 0.2 mm to −1.94 mm with respect to Bregma according to a stereotaxic atlas of the mouse brain (Franklin and Paxinos 1997). The thickness of the S2 somatosensory cerebral cortex, as well as the horizontal distance from left–right corpus callosum at mid dorsal-to-ventral level, were measured using an ocular micrometer. A subset of these tissue sections was digitized at 20× magnification (three frames per section) throughout the entire cerebral cortex, and the total cell number was quantified manually from printouts.

Cell counts

For astrocyte counts, cryostat sections from brains (4–6 mo old) were serially cut at 50-µm thickness and subjected to GFAP immunohistochemistry as described above. The number of GFAP-positive cells was counted in one out of each seven sections. For the cerebral cortex, the regions containing motor and somatosensory cortex were chosen, for the hippocampus, a rectangle covering both CA1 and dentate gyrus was introduced, and the number of GFAP-positive cells was determined in the rectangle of each section. For the brainstem, the regions containing the facial nucleus were analyzed.

Western blot analysis

Brains were dissected into regions including cortex, hippocampus, brainstem, and cerebellum and frozen in liquid nitrogen. Proteins were extracted and subjected to Western blot analysis as previously described (Klesse and Parada 1998). The dilutions of primary antibodies used were: P-erk (1:1000, Biolabs) and erk (1:5000, Santa Cruz). Densitometry analysis was performed with the Molecular Dynamics Computing Densitometry (300A).

Statistical analysis

The values were compared using a two-way ANOVA (Super ANOVA program, Abacus Concepts) to evaluate for differences caused by phenotype and anterior-to-posterior level. One-way ANOVA with these two variables combined, followed by Student-Newman-Keuls post-hoc test, was used to determine differences in individual groups. P-values < 0.05 were considered to be significant.

BrdU assay and tumor analysis

Neonatal mutant and control littermates (P0) were pulsed with BrdU for 2 h and adult [5-month-old] mice were pulsed with BrdU five times at 2-h intervals. The dose of BrdU was 50 µg/g (body weight). BrdU-treated mice were fixed and processed as described above. BrdU immunohistochemistry was performed as described previously [Zhu et al. 1998]. The dilution of primary BrdU antibody was 1:50 [Becton Dickinson].

In total, 29 NF1<sup>SynIKO</sup> mice were monitored over a period of 14 mo. Complete necropsy was performed under a dissecting microscope, and the brains were subjected to histological analysis (see above). Five of these 29, 14-month-old mice were perfused as described above, and spinal column was postfixed in
4% paraformaldehyde at 4°C overnight. The next day, the entire spinal cords with DRGs were dissected and fixed in 4% paraformaldehyde at 4°C overnight. Fixed tissues were then processed and paraffin embedded. Paraffin sections were serially cut at 5-µm thickness, stained with H&E, and examined under light microscope.

Acknowledgments

We thank David Anderson for gift of the β-actin/LacZ reporter mice and Nancy Ratner and David Gutmann for providing NFI antibody. We thank Steve Kernie for critical reading of the manuscript and all members of the Parada Lab for helpful discussions and support. We thank Tammy Oliver for assistance with histology. J.F.P acknowledges support from: NINDS-R01-NS34296-05; DAMD 17-97-1-7343; the National Neurofibromatosis Foundation, and the Texas Neurofibromatosis Foundation. We thank Thierry Hennet and Michael Durnin for assistance in generating the Syn1-Cre transgenic mice. J.D.M. acknowledges support from NIH grant DK48247. J.D.M. is an Investigator of the Howard Hughes Medical Institute.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact.

References

Baba, H., Fuss, B., Urano, J., Pouillet, P., Watson, J.B., Tamanai, F., and Macklin, W.B. 1995. CapGlp, a new brain-enriched member of the GTPase-activating protein family. J. Neurosci. Res. 41: 846–858.

Ballester, R., Marchuk, D., Boguski, M., Saulino, A., Letcher, R., Wigler, M., and Collins, F. 1990. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63: 851–859.

Basu, T.N., Gutmann, D.H., Fletcher, J.A., Glover, T.W., Collins, F.S., and Downward, J. 1992. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356: 713–715.

Bollag, G., Clapp, D.W., Boguski, M.S., Saulino, A., Letcher, R., Wigler, M., and Collins, F. 1990. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63: 851–859.

Bosl, J.W. 1989. ras oncogenes in human cancer: A review. Cancer Res. 49: 4682–4689.

Bourne, H.R., Sanders, D.A., and McCormick, F. 1990. The GTPase superfamily: A conserved switch for diverse cell functions. Nature 348: 125–132.

Branman, C.L., Perkins, A.S., Vogel, K.S., Ratner, N., Nordlund, M.L., Reid, S.W., Buchberg, A.M., Jenkins, N.A., Parada, L.F., and Copeland, N.G. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes & Dev. 8: 1019–1029.

Buchberg, A.M., Cleveland, L.S., Jenkins, N.A., and Copeland, N.G. 1990. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 347: 291–294.

Cawthon, R.M., Weiss, R., Xu, G.F., Viskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., O’Connell, P., et al. 1990. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62: 193–201.

Colman, S.D., Williams, C.A., and Wallace, M.R. 1995. Benign neurofibromas in type 1 neurofibromatosis [NF1] show somatic deletions of the NFI gene. Nat. Genet. 11: 90–92.

Daston, M.M. and Ratner, N. 1992. Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development. Dev. Dyn. 195: 216–226.

Daston, M.M., Scrahle, H., Nordlund, M., Sturbaum, A.K., Nissen, L.M., and Rate, N. 1992. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 8: 415–428.

DeClue, J.E., Cohen, B.D., and Lowy, D.R. 1991. Identification and characterization of the neurofibromatosis type 1 protein product. Proc. Nat. Acad. Sci. 88: 9914–9918.

DeClue, J.E., Papageorge, A.G., Fletcher, J.A., Diehl, S.R., Ratner, N., Vass, W.C., and Lowy, D.R. 1992. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen [type 1] neurofibromatosis. Cell 69: 265–273.

Dono, Ro, Tizado, G., Dussel, R., Ehmkhe, H., and Zeller, R. 1998. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J. 17: 4213–4225.

Franklin, K.B.J. and Paxinos, G. 1997. The mouse brain in stereotaxic coordinates. Academic Press, San Diego, CA.

Gaul, U., Mardon, G., and Rubin, G.M. 1992. A putative Ras GTPase activating protein acts as a negative regulator of signaling by the Sevenless receptor tyrosine kinase. Cell 68: 1007–1019.

Ghebranious, N. and Domehower, L.A. 1999. Mouse models in tumor suppression. Oncogene 17: 5385–5400.

Glasier, E.M. and Van der Loos, H. 1981. Analysis of thick brain sections by obverse-reverse computer microscopy: Application of a new, high clarity Golgi-Nissl stain. J. Neurosci. Methods 4: 117–125.

Gu, H., Smith, J.D., Orban, P.C., Mossmann, H., and Rajewsky, K. 1994. Deletion of a DNA polymerase β gene segment in T cells using cell type-specific gene targeting. Science 265: 103–106.

Guo, H.F., The, I., Hannan, F., Bernards, A., and Zhong, Y. 1997. Requirement of Drosophila NFI for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 276: 795–798.

Guo, H.F., Tong, J., Hannan, F., Luo, L., and Zhong, Y. 2000. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 403: 895–898.

Gutmann, D.H., Aylsworth, A., Carey, J.C., Korf, B., Mark S., Pyeritz, R.E., Rubenstein, A., and Viskochil, D. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. J. Am. Med. Assoc. 278: 51–57.

Gutmann, D.H., Loehr, A., Zang, Y., Kim, J., Henkemeier, M., and Cashen, A. 1999. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 18: 4450–4459.

Gutmann, D.H., Wood, D.L., and Collins, F.S. 1991. Identification of the neurofibromatosis type 1 gene product. Proc. Natl. Acad. Sci. 88: 9658–9662.

Hatten, M.E. 1999. Central nervous system neuronal migration. Annu. Rev. Neurosci. 22: 511–539.

Hayashi, Y., Ueki, K., Waha, A., Wiestler, O.D., Louis, D.N., and von Deimling, A. 1997. Association of EGFR gene amplification and CDKN2 [p16/MST1] gene deletion in gli-
NF1 conditional knockouts exhibit astrogliosis

Hoesche, C., Sauerwald, A., Veh, R.W., Krippl, B., and Kilimann, M.W. 1993. The 5′-flanking region of the rat synapsin I gene directs neuron-specific and developmentally regulated reporter gene expression in transgenic mice. J. Biol. Chem. 268:26494-26502.

Huybers, D.P., Nechiporuk, T., and Pulst, S.M. 1994. Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development. Dev. Biol. 161: 538–551.

Jacks, T. 1996. Tumor suppressor gene mutations in mice. Annu. Rev. Genet. 30: 603–636.

Johnson, M.R., DeClue, J.E., Felzmann, S., and Weinberg, R.A. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in NF1. Nat. Genet. 7: 353–361.

Legius, E., Marchak, D.A., Collins, F.S., and Glover, T.W. 1993. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat. Genet. 3: 122–126.

Li, Y., O’Connell, P., Breidenbach, H.H., Cawthon, R., Stevens, J., Xu, G., Neil, S., Robertson, M., White, R., and Viskochil, D. 1995. Genomic organization of the neurofibromatosis 1 gene [NF1]. Genomics 25: 9–18.

Mandell, J.W. and Vandenberg, S.R. 1999. ERK/MAP kinase is chronically activated in human reactive astrocytes. Neuronreport 10: 3567–3572.

Martin, G.A., Viskochil, D., Bollag, G., McCabe, P.C., Crosier, W.J., Haubruck, H., Comoy, L., Clark, R., O’Connell, P., Cawthon, R.M., et al. 1990. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63: 843–849.

McClatchey, A.L. and Jacks, T. 1998. Tumor suppressor mutations in mice: The next generation. Curr. Opin. Genet. Dev. 8: 304–310.

Melloni, R.H., Jr. and DeGennaro, L.J. 1994. Temporal onset of synapsin I gene expression coincides with neuronal differentiation during the development of the nervous system. J. Comp. Neurol. 342: 449–462.

Mullen, R.J., Buck, C.R., and Smith, A.M. 1992. NeuN, a neuronal specific nuclear protein in vertebrates. Development 116: 201–211.

Nordlund, M., Xu, J., Shipley, M.T., and Ratner, N. 1993. Neurofibromin is enriched in the endoplasmic reticulum of CNS neurons. J. Neurosci. 13: 1588–1600.

Nordlund, M.L., Rizvi, T.A., Brannan, C.I., and Ratner, N. 1995. Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains. J. Neuropathol. Exp. Neurol. 54: 588–600.

North, K. 1999. Cognitive function and academic performance. In Neurofibromatosis: Phenotype, natural history, and pathogenesis [ed. J.M. Friedman, D.H. Gutmann, M. MacCollin, and V.M. Riccardi], pp. 162–189. Johns Hopkins Press, Baltimore, MD.

Peltonen, J., Jaakkola, S., Lebwohl, M., Renvall, S., Risteli, L., Virtanen, I., and Uitto, J. 1988. Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. Lab. Invest. 59: 760–771.

Rachbevsky, A.G., Weinitz, J.M., Couplier, M., Fages, C., Tinel, M., and Junier, M.P. 1998. A role for transforming growth factor alpha as an inducer of astrogliosis. J. Neurosci. 18: 10541–10552.

Ramon y Cajal, S. 1904. Histology of the nervous system. Oxford University Press, New York and UK.

Riccardi, V.M. 1999. Historical background and introduction. In Neurofibromatosis: phenotype, natural history, and pathogenesis. [ed. J.M. Friedman, D.H. Gutmann, M. MacCollin, and V.M. Riccardi], pp. 1–25. Johns Hopkins Press, Baltimore, MD.

Ridet, J.L., Malhotra, S.K., Privat, A., and Gage, F.H. 1997. Reactive astrocytes: Cellular and molecular cues to biological function. Trends Neurosci. 20: 570–577.

Rizvi, T.A., Akunuru, S., de Courten-Myers, G., Switzer III, R.C., Nordlund, M.L., and Ratner, N. 1999. Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 [NF1] tumor suppressor. Brain Res. 816: 111–123.

Rosenbaum, T., Boissy, Y.L., Kombrinck, K., Brannan, C.I., Jenkins, N.A., Copeland, N.G., and Ratner, N. 1995. Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. Development 121: 3583–3592.

Rosman, N.P. and Pearce, J. 1967. The brain in multiple neurofibromatosis (von Recklinghausen’s disease): A suggested neuropathological basis for the associated mental defect. Brain 90: 829–838.

Sawada, S., Florell, S., Purandare, S.M., Ota, M., Stephens, K., and Viskochil, D. 1996. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat. Genet. 14: 110–112.

Schlegel, J., Mirdes, A., Stumm, G., Albert, F.K., Forsting, M., Hynes, N., and Kiessling, M. 1994. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int. J. Cancer 56: 72–77.

Side, L., Taylor, B., Cayouette, M., Conner, E., Thompson, P., Luce, M., and Shannon, K. 1997. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med. 336: 1713–1720.

Silva, A.J., Frankland, P.W., Marowitz, Z., Friedman, E., Lazo, G., Cioffi, D., Jacks, T., and Bourculeadze, R. 1997. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat. Genet. 15: 281–284.

Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21: 70–71.

Steward, O., Torre, E.R., Tomasulo, R., and Lothman, E. 1991. Neuronal activity up-regulates astroglial gene expression. Proc. Natl. Acad. Sci. 88: 6819–6823.

Streit, W.J., Walter, S.A., and Pennell, N.A. 1999. Reactive microgliosis. Prog. Neurobiol. 57: 563–581.

Tanaka, K., Nakafuku, M., Sato, T., Marshall, M.S., Gibbs, J.B., Matsumoto, K., Kaziro, Y., and Toh-e, A. 1990. S. cerevisiae genes IRA1 and IRA2 encode proteins that may be functionally equivalent to mammalian ras GTPase activating pro-
tein. Cell 60: 803–807.
The, I., Hannigan, G.E., Cowley, G.S., Reginald, S., Zhong, Y.,
Gusella, J.F., Hartharan, I.K., and Bernards, A. 1997. Rescue
of a Drosophila NF1 mutant phenotype by protein kinase A.
Science 276: 791–794.
Trahey, M. and McCormick, F. 1987. A cytoplasmic protein
stimulates normal N-ras p21 GTPase, but does not affect
oncogenic mutants. Science 238: 542–545.
Trahey, M., Wong, G., Halenbeck, R., Rubinfeld, B., Martin,
G.A., Ladner, M., Long, C.M., Crosier, W.J., Watt, K., Koths,
K., et al. 1988. Molecular cloning of two types of GAP
complementary DNA from human placenta. Science
242: 1697–1700.
Tsien, J.Z., Chen, D.F., Gerber, D., Tom, C., Mercer, E.H.,
Anderson, D.J., Mayford, M., Kandel, E.R., and Tonegawa, S.
1996. Subregion- and cell type-restricted gene knockout in
mouse brain. Cell 87: 1317–1326.
Upadhyaya, M., Shaw, D.J., and Harper, P.S. 1994. Molecular
basis of neurofibromatosis type 1 (NF1): Mutation analysis
and polymorphisms in the NF1 gene. Hum. Mutat. 4: 83–
101.
van der Geer, P., Henkemeyer, M., Jacks, T., and Pawson, T.
1997. Aberrant Ras regulation and reduced p190 tyrosine
phosphorylation in cells lacking p120-Gap. Mol. Cell. Biol.
17: 1840–1847.
Viskochil, D.H. 1999. The structure and function of the NF1
gene: Molecular pathology. In Neurofibromatosis: Pheno-
type, natural history, and pathogenesis (ed. J.M. Friedman,
D.H. Gutmann, M. MacCollin, and V.M. Riccardi), pp. 119–
141. Johns Hopkins Press, Baltimore, MD.
Viskochil, D., Buchberg, A.M., Xu, G., Cawthon, R.M., Stevens,
J., Wolff, R.K., Culver, M., Carey, J.C., Copeland, N.G., Jen-
kins, N.A., et al. 1990. Deletions and a translocation inter-
rupt a cloned gene at the neurofibromatosis type 1 locus.
Cell 62: 187–192.
Vogel, K.S., Brannan, C.I., Jenkins, N.A., Copeland, N.G., and
Parada, L.F. 1995. Loss of neurofibromin results in neuro-
trophin-independent survival of embryonic sensory and
sympathetic neurons. Cell 82: 733–742.
Vogel, U.S., Dixon, R.A., Schaber, M.D., Diehl, R.E., Marshall,
M.S., Scolnick, E.M., Sigal, I.S., and Gibbs, J.B. 1988. Cloning
of bovine GAP and its interaction with oncogenic ras p21.
Nature 335: 90–93.
Voiculescu, O., Charnay, P., and Schneider-Maunoury, S. 2000.
Expression pattern of a Krox-20/Cre knock-in allele in the
developing hindbrain, bones, and peripheral nervous system.
Genesis 26: 123–126.
Wallace, M.R., Marchuk, D.A., Andersen, L.B., Letcher, R.,
Odeh, H.M., Saulino, A.M., Fountain, J.W., Brereton, A., Ni-
cholson, J., Mitchell, A.L., et al. 1990. Type 1 neurofibroma-
tosis gene: Identification of a large transcript disrupted in
three NF1 patients. Science 249: 181–186.
Xu, G.F., O'Connell, P., Viskochil, D., Cawthon, R., Robertson,
M., Culver, M., Dunn, D., Stevens, J., Gesteland, R., White,
R., et al. 1990. The neurofibromatosis type 1 gene encodes a
protein related to GAP. Cell 62: 599–608.
Xu, W., Mulligan, L.M., Ponder, M.A., Liu, L., Smith, B.A.,
Mathew, C.G., and Ponder, B.A. 1992. Loss of NF1 alleles in
pheochromocytomas from patients with type I neurofibro-
matosis. Genes Chromosomes Cancer 4: 337–342.
Zhu, Y. and Parada, L.F. 2001. Neurofibromin, a tumor suppres-
sor in the nervous system. Exp. Cell. Res. 264: 19–28.
Zhu, Y., Richardson, J.A., Parada, L.F., and Graff, J.M. 1998.
Smad3 mutant mice develop metastatic colorectal cancer.
Cell 94: 703–714.
Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain

Yuan Zhu, Mario I. Romero, Pritam Ghosh, et al.

Genes Dev. 2001, 15:
Access the most recent version at doi:10.1101/gad.862101

References
This article cites 74 articles, 21 of which can be accessed free at:
http://genesdev.cshlp.org/content/15/7/859.full.html#ref-list-1

License

Email Alerting Service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.